CDK9-IN-9

• UNSPSC Description:

  CDK9-IN-9 (example 2) is a potent and selective CDK9 inhibitor with an IC50 of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC50 of 155 nM. CDK9-IN-9 has anti-cancer activity[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk9-in-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CS(CC1=CC2=CC(NC3=NC=C(C(C4=CC=C(C(NCCCCO2)=C4)F)=N3)F)=C1)(=O)=N

• Molecular Weight:

  459.51

• References & Citations:

  [1]Ulrich LÜCKING, et al. Novel ptefb inhibiting macrocyclic compounds. WO2018177889A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2246956-84-1